secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001823239-24-000058
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q1 revenue down 19% to $64.2M; net loss widens to $22.7M; FY guide reaffirmed
--------------------------------------------------------------------------------

- Quarterly revenue $64.2M, down 19% YoY; Nucleic Acid Production fell 25% to $46.0M.
- Net loss of $22.7M vs $1.3M loss in Q1 2023; Adjusted EBITDA $7.8M vs $23.8M.
- Biologics Safety Testing revenue up 3.4% to $18.2M.
- Reaffirmed FY2024 revenue guidance $265M–$285M.
- Entered non-exclusive CleanCap license agreement with Lonza for mRNA services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323924000058/0001823239-24-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323924000058/mrvi-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001823239-24-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer